Previous 10 | Next 10 |
EyeGate Pharmaceuticals (NASDAQ: EYEG ) hits the enrollment target in a follow-on pilot study evaluating its Ocular Bandage Gel eye drop in patients with punctate epitheliopathies, mainly dry eye. More news on: EyeGate Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, ...
Aimmune Therapeutics, Inc. (AIMT) has been quite a sprightly stock lately, and it has a couple of key events coming up as well. However, the firm also faces a few obstacles, the foremost being the FDA's stepmotherly attitude over the years. Its lead drug candidate Palforzia was approved by t...
WALTHAM, MA / ACCESSWIRE / January 3, 2020 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, today announced the completion of its previously announced registered direct offer...
Gainers: Neovasc (NASDAQ: NVCN ) +70% . More news on: Neovasc Inc., Inpixon, FuelCell Energy, Inc., Stocks on the move, Read more ...
WALTHAM, MA / ACCESSWIRE / December 31, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, today announced that it has entered into a definitive agreement with certain ins...
Gainers: Savara (NASDAQ: SVRA ) +98% . More news on: Savara Inc., NIO Limited, Sol-Gel Technologies Ltd., Stocks on the move, Read more ...
WALTHAM, MA / ACCESSWIRE / December 17, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company") announced today that it has received approximately $1.9 million from the exercise of warrants subsequent to the release of positive topline data on November 22, 2019 for it...
Image Source: OPIS Company Thesis EyeGate's ( EYEG ) recent Phase 3 interim data release on its lead candidate, Ocular Bandage Gel, demonstrated significant evidence favoring the drug's approval. Its formulation as an eye drop instead of a contact lens should also aid in sales and ...
WALTHAM, MA / ACCESSWIRE / December 2, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has received additional positive topline data in its corn...
Positive Pivotal Top-Line data EyeGate Pharmaceuticals, Inc . ( EYEG ) is a clinical stage specialty pharmaceutical company that develops products for treating eye diseases and disorders. On Nov 22, 2019, EYEG announced that their PRK (photorefractive keratectomy) study has met its pr...
News, Short Squeeze, Breakout and More Instantly...
Eyegate Pharmaceuticals Inc. Company Name:
EYEG Stock Symbol:
NASDAQ Market:
LONDON, UK / ACCESSWIRE / December 9, 2022 / Kazia Therapeutics has announced the publication of pre-clinical data for its second pipeline asset, EVT801 in the journal Cancer Research Communications. The research was conducted by licensing partner Evotec and was the key driver for Kazia in-licen...
LONDON, UK / ACCESSWIRE / December 7, 2022 / With its H123 interim results, ReNeuron highlighted progress across its proprietary exosome platform, CustomEx. The company reported H123 revenues of £438k (H122: £58k), primarily related to income associated with a £320k payment from F...
WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announc...